Previous studies that assessed the comprehensive mutational landscape of NSCLC reported that smoking exposure enhanced somatic mutations, thereby could increase tumor response to anti-PD-1/PD-L1 therapy 1, 11. Here, RPL17 is linked to non-small cell lung carcinoma.